{"count": 24, "results": [{"_id": "35405370", "pmid": 35405370, "pmcid": "PMC9048115", "title": "Metformin overcomes metabolic reprogramming-induced resistance of skin squamous cell carcinoma to photodynamic therapy", "journal": "Mol Metab", "authors": ["Mascaraque-Checa M", "Gallego-Rentero M", "Nicolás-Morala J", "Portillo-Esnaola M", "Cuezva JM", "González S", "Gilaberte Y", "Juarranz Á"], "date": "2022-06-01T00:00:00Z", "doi": "10.1016/j.molmet.2022.101496", "meta_date_publication": "2022 Jun", "meta_volume": "60", "meta_issue": "", "meta_pages": "101496", "score": 50279.004, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ overcomes metabolic reprogramming-induced resistance of @<m>DISEASE_Carcinoma_Squamous_Cell</m> @DISEASE_MESH:D002294 @@@skin squamous cell carcinoma@@@ to photodynamic therapy", "citations": {"NLM": "Mascaraque-Checa M, Gallego-Rentero M, Nicolás-Morala J, Portillo-Esnaola M, Cuezva JM, González S, Gilaberte Y, Juarranz Á. Metformin overcomes metabolic reprogramming-induced resistance of skin squamous cell carcinoma to photodynamic therapy Mol Metab. 2022 Jun;60():101496. PMID: 35405370", "BibTeX": "@article{35405370, title={Metformin overcomes metabolic reprogramming-induced resistance of skin squamous cell carcinoma to photodynamic therapy}, author={Mascaraque-Checa M and Gallego-Rentero M and Nicolás-Morala J and Portillo-Esnaola M and Cuezva JM and González S and Gilaberte Y and Juarranz Á}, journal={Mol Metab}, volume={60}, pages={101496}}"}}, {"_id": "33262518", "pmid": 33262518, "pmcid": "PMC7921644", "title": "Metformin use and lung cancer survival: a population-based study in Norway", "journal": "Br J Cancer", "authors": ["Brancher S", "Støer NC", "Weiderpass E", "Damhuis RAM", "Johannesen TB", "Botteri E", "Strand TE"], "date": "2021-03-01T00:00:00Z", "doi": "10.1038/s41416-020-01186-9", "meta_date_publication": "2021 Mar", "meta_volume": "124", "meta_issue": "5", "meta_pages": "1018-1025", "score": 50273.336, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ use was associated with improved survival, especially @DISEASE_Lung_Neoplasms @DISEASE_MESH:D008175 @@@LCSS@@@ in @SPECIES_9606 @@@patients@@@ with regional stage @<m>DISEASE_Carcinoma_Squamous_Cell</m> @DISEASE_MESH:D002294 @@@SCC@@@. ", "citations": {"NLM": "Brancher S, Støer NC, Weiderpass E, Damhuis RAM, Johannesen TB, Botteri E, Strand TE. Metformin use and lung cancer survival: a population-based study in Norway Br J Cancer. 2021 Mar;124(5):1018-1025. PMID: 33262518", "BibTeX": "@article{33262518, title={Metformin use and lung cancer survival: a population-based study in Norway}, author={Brancher S and Støer NC and Weiderpass E and Damhuis RAM and Johannesen TB and Botteri E and Strand TE}, journal={Br J Cancer}, volume={124}, number={5}, pages={1018-1025}}"}}, {"_id": "40901390", "pmid": 40901390, "title": "Antitumor Effects of Metformin in Squamous Cell Carcinoma under Leptin Treatment Conditions.", "journal": "Prev Nutr Food Sci", "authors": ["Yeom S", "Jo D", "Choi SY", "Ahn SY", "Lee DH", "Song J"], "date": "2025-08-31T00:00:00Z", "doi": "10.3746/pnf.2025.30.4.312", "meta_date_publication": "2025 Aug 31", "meta_volume": "30", "meta_issue": "4", "meta_pages": "312-322", "score": 50262.668, "text_hl": "Antitumor Effects of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ in @<m>DISEASE_Carcinoma_Squamous_Cell</m> @DISEASE_MESH:D002294 @@@Squamous Cell Carcinoma@@@ under @GENE_LEP @GENE_3952 @@@Leptin@@@ Treatment Conditions.", "citations": {"NLM": "Yeom S, Jo D, Choi SY, Ahn SY, Lee DH, Song J. Antitumor Effects of Metformin in Squamous Cell Carcinoma under Leptin Treatment Conditions. Prev Nutr Food Sci. 2025 Aug 31;30(4):312-322. PMID: 40901390", "BibTeX": "@article{40901390, title={Antitumor Effects of Metformin in Squamous Cell Carcinoma under Leptin Treatment Conditions.}, author={Yeom S and Jo D and Choi SY and Ahn SY and Lee DH and Song J}, journal={Prev Nutr Food Sci}, volume={30}, number={4}, pages={312-322}}"}}, {"_id": "32083006", "pmid": 32083006, "pmcid": "PMC7005048", "title": "Hexokinase 2 Depletion Confers Sensitization to Metformin and Inhibits Glycolysis in Lung Squamous Cell Carcinoma", "journal": "Front Oncol", "authors": ["Guo W", "Kuang Y", "Wu J", "Wen D", "Zhou A", "Liao Y", "Song H", "Xu D", "Wang T", "Jing B", "Li K", "Hu M", "Ling J", "Wang Q", "Wu W"], "date": "2020-01-31T00:00:00Z", "doi": "10.3389/fonc.2020.00052", "meta_date_publication": "2020", "meta_volume": "10", "meta_issue": "", "meta_pages": "52", "score": 50257.48, "text_hl": "@GENE_HK2 @GENE_3099 @@@Hexokinase 2@@@ Depletion Confers Sensitization to @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ and Inhibits Glycolysis in @<m>DISEASE_Carcinoma_Squamous_Cell</m> @DISEASE_MESH:D002294 @@@Lung Squamous Cell Carcinoma@@@", "citations": {"NLM": "Guo W, Kuang Y, Wu J, Wen D, Zhou A, Liao Y, Song H, Xu D, Wang T, Jing B, Li K, Hu M, Ling J, Wang Q, Wu W. Hexokinase 2 Depletion Confers Sensitization to Metformin and Inhibits Glycolysis in Lung Squamous Cell Carcinoma Front Oncol. 2020;10():52. PMID: 32083006", "BibTeX": "@article{32083006, title={Hexokinase 2 Depletion Confers Sensitization to Metformin and Inhibits Glycolysis in Lung Squamous Cell Carcinoma}, author={Guo W and Kuang Y and Wu J and Wen D and Zhou A and Liao Y and Song H and Xu D and Wang T and Jing B and Li K and Hu M and Ling J and Wang Q and Wu W}, journal={Front Oncol}, volume={10}, pages={52}}"}}, {"_id": "35569426", "pmid": 35569426, "pmcid": "PMC9111182", "title": "Metformina en el tratamiento de enfermedades dermatologicas: una revision narrativa", "journal": "Aten Primaria", "authors": ["Monte-Serrano J", "Villagrasa-Boli P", "Cruañes-Monferrer J", "Arbués-Espinosa P", "Martínez-Cisneros S", "García-Gil MF"], "date": "2022-06-01T00:00:00Z", "doi": "10.1016/j.aprim.2022.102354", "meta_date_publication": "2022 Jun", "meta_volume": "54", "meta_issue": "6", "meta_pages": "102354", "score": 50257.348, "text_hl": "Concretamente, los pacientes en tratamiento con @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformina@@@ presentaban un hazard ratio (HR) de 0,62 en cuanto a desarrollo de @<m>DISEASE_Carcinoma_Squamous_Cell</m> @DISEASE_MESH:D002294 @@@carcinoma epidermoide@@@, en comparacion con aquellos que no recibian tratamiento con @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformina@@@. ", "citations": {"NLM": "Monte-Serrano J, Villagrasa-Boli P, Cruañes-Monferrer J, Arbués-Espinosa P, Martínez-Cisneros S, García-Gil MF. Metformina en el tratamiento de enfermedades dermatologicas: una revision narrativa Aten Primaria. 2022 Jun;54(6):102354. PMID: 35569426", "BibTeX": "@article{35569426, title={Metformina en el tratamiento de enfermedades dermatologicas: una revision narrativa}, author={Monte-Serrano J and Villagrasa-Boli P and Cruañes-Monferrer J and Arbués-Espinosa P and Martínez-Cisneros S and García-Gil MF}, journal={Aten Primaria}, volume={54}, number={6}, pages={102354}}"}}, {"_id": "33610593", "pmid": 33610593, "title": "Metformin is associated with decreased risk of basal cell carcinoma: A whole-population case-control study from Iceland.", "journal": "J Am Acad Dermatol", "authors": ["Adalsteinsson JA", "Muzumdar S", "Waldman R", "Wu R", "Ratner D", "Feng H", "Ungar J", "Silverberg JI", "Olafsdottir GH", "Kristjansson AK", "Tryggvadottir L", "Jonasson JG"], "date": "2021-07-01T00:00:00Z", "doi": "10.1016/j.jaad.2021.02.042", "meta_date_publication": "2021 Jul", "meta_volume": "85", "meta_issue": "1", "meta_pages": "56-61", "score": 50256.062, "text_hl": "OBJECTIVES: To delineate the association between @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ use and invasive @<m>DISEASE_Carcinoma_Squamous_Cell</m> @DISEASE_MESH:D002294 @@@SCC@@@, @<m>DISEASE_Carcinoma_Squamous_Cell</m> @DISEASE_MESH:D002294 @@@SCC in situ@@@ (@<m>DISEASE_Carcinoma_Squamous_Cell</m> @DISEASE_MESH:D002294 @@@SCCis@@@), and @DISEASE_Carcinoma_Basal_Cell @DISEASE_MESH:D002280 @@@BCC@@@. ", "citations": {"NLM": "Adalsteinsson JA, Muzumdar S, Waldman R, Wu R, Ratner D, Feng H, Ungar J, Silverberg JI, Olafsdottir GH, Kristjansson AK, Tryggvadottir L, Jonasson JG. Metformin is associated with decreased risk of basal cell carcinoma: A whole-population case-control study from Iceland. J Am Acad Dermatol. 2021 Jul;85(1):56-61. PMID: 33610593", "BibTeX": "@article{33610593, title={Metformin is associated with decreased risk of basal cell carcinoma: A whole-population case-control study from Iceland.}, author={Adalsteinsson JA and Muzumdar S and Waldman R and Wu R and Ratner D and Feng H and Ungar J and Silverberg JI and Olafsdottir GH and Kristjansson AK and Tryggvadottir L and Jonasson JG}, journal={J Am Acad Dermatol}, volume={85}, number={1}, pages={56-61}}"}}, {"_id": "39630677", "pmid": 39630677, "title": "Metformin Use and Risk of Non-Melanoma Skin Cancer: A Propensity-Matched Case-Control Study.", "journal": "J Drugs Dermatol", "authors": ["Haq Z", "Mirza FN", "Abdi P", "Diaz MJ", "Libby TJ"], "date": "2024-12-01T00:00:00Z", "doi": "10.36849/jdd.8249", "meta_date_publication": "2024 Dec 1", "meta_volume": "23", "meta_issue": "12", "meta_pages": "1089-1095", "score": 50255.13, "text_hl": "However, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ exposure was not significantly associated with decreased @<m>DISEASE_Carcinoma_Squamous_Cell</m> @DISEASE_MESH:D002294 @@@SCC@@@ risk in African American @SPECIES_9606 @@@patients@@@. ", "citations": {"NLM": "Haq Z, Mirza FN, Abdi P, Diaz MJ, Libby TJ. Metformin Use and Risk of Non-Melanoma Skin Cancer: A Propensity-Matched Case-Control Study. J Drugs Dermatol. 2024 Dec 1;23(12):1089-1095. PMID: 39630677", "BibTeX": "@article{39630677, title={Metformin Use and Risk of Non-Melanoma Skin Cancer: A Propensity-Matched Case-Control Study.}, author={Haq Z and Mirza FN and Abdi P and Diaz MJ and Libby TJ}, journal={J Drugs Dermatol}, volume={23}, number={12}, pages={1089-1095}}"}}, {"_id": "33278671", "pmid": 33278671, "title": "Randomized phase II study of platinum-based chemotherapy plus controlled diet with or without metformin in patients with advanced non-small cell lung cancer.", "journal": "Lung Cancer", "authors": ["Lee Y", "Joo J", "Lee YJ", "Lee EK", "Park S", "Kim TS", "Lee SH", "Kim SY", "Wie GA", "Park M", "Kim MJ", "Lee JS", "Han JY"], "date": "2021-01-01T00:00:00Z", "doi": "10.1016/j.lungcan.2020.11.011", "meta_date_publication": "2021 Jan", "meta_volume": "151", "meta_issue": "", "meta_pages": "8-15", "score": 50250.254, "text_hl": "In the @<m>DISEASE_Carcinoma_Squamous_Cell</m> @DISEASE_MESH:D002294 @@@SqCC@@@ with high @CHEMICAL_Fluorodeoxyglucose_F18 @CHEMICAL_MESH:D019788 @@@FDG@@@ uptake, the addition of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ significantly decreased the risk of progression and @DISEASE_Death @DISEASE_MESH:D003643 @@@death@@@ (progression: HR = 0.31 [95% CI = 0.12-0.78], P = 0.013; @DISEASE_Death @DISEASE_MESH:D003643 @@@death@@@: HR = 0.42 [95% CI = 0.18-0.94], P = 0.035). ", "citations": {"NLM": "Lee Y, Joo J, Lee YJ, Lee EK, Park S, Kim TS, Lee SH, Kim SY, Wie GA, Park M, Kim MJ, Lee JS, Han JY. Randomized phase II study of platinum-based chemotherapy plus controlled diet with or without metformin in patients with advanced non-small cell lung cancer. Lung Cancer. 2021 Jan;151():8-15. PMID: 33278671", "BibTeX": "@article{33278671, title={Randomized phase II study of platinum-based chemotherapy plus controlled diet with or without metformin in patients with advanced non-small cell lung cancer.}, author={Lee Y and Joo J and Lee YJ and Lee EK and Park S and Kim TS and Lee SH and Kim SY and Wie GA and Park M and Kim MJ and Lee JS and Han JY}, journal={Lung Cancer}, volume={151}, pages={8-15}}"}}, {"_id": "33047438", "pmid": 33047438, "title": "The association of metformin use with keratinocyte carcinoma development in high-risk patients.", "journal": "Dermatol Ther", "authors": ["Misitzis A", "Stratigos AJ", "Beatson M", "Mastorakos G", "Dellavalle RP", "Weinstock MA", "Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial Group"], "date": "2020-11-01T00:00:00Z", "doi": "10.1111/dth.14402", "meta_date_publication": "2020 Nov", "meta_volume": "33", "meta_issue": "6", "meta_pages": "e14402", "score": 50248.574, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@-users compared to non-users had a significantly lower risk for @<m>DISEASE_Carcinoma_Squamous_Cell</m> @DISEASE_MESH:D002294 @@@squamous cell carcinoma@@@ with an adjusted Hazard ratio (HR): 0.45, (CI: 0.24-0.84, P < .01) and @DISEASE_Carcinoma_Basal_Cell @DISEASE_MESH:D002280 @@@basal cell carcinoma@@@ (HR: 0.70, CI: 0.49-0.97, P < .03). ", "citations": {"NLM": "Misitzis A, Stratigos AJ, Beatson M, Mastorakos G, Dellavalle RP, Weinstock MA, Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial Group. The association of metformin use with keratinocyte carcinoma development in high-risk patients. Dermatol Ther. 2020 Nov;33(6):e14402. PMID: 33047438", "BibTeX": "@article{33047438, title={The association of metformin use with keratinocyte carcinoma development in high-risk patients.}, author={Misitzis A and Stratigos AJ and Beatson M and Mastorakos G and Dellavalle RP and Weinstock MA and Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial Group}, journal={Dermatol Ther}, volume={33}, number={6}, pages={e14402}}"}}, {"_id": "37669776", "pmid": 37669776, "title": "Metformin shows anti-neoplastic properties by inhibition of oxidative phosphorylation and glycolysis in epidermolysis bullosa-associated aggressive cutaneous squamous cell carcinoma.", "journal": "J Eur Acad Dermatol Venereol", "authors": ["Welponer T", "Weber DD", "Trattner L", "Tockner B", "Aminzadeh-Gohari S", "Leb-Reichl V", "Kaufmann A", "Zauner R", "Wimmer M", "Wally V", "Felder TK", "Strunk D", "Koller U", "Bauer JW", "Kofler B", "Guttmann-Gruber C", "Hofbauer JP"], "date": "2023-09-05T00:00:00Z", "doi": "10.1111/jdv.19488", "meta_date_publication": "2023 Sep 5", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50247.992, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ shows anti-@DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@neoplastic@@@ properties by inhibition of oxidative phosphorylation and glycolysis in @DISEASE_Epidermolysis_Bullosa @DISEASE_MESH:D004820 @@@epidermolysis bullosa@@@-associated aggressive @<m>DISEASE_Carcinoma_Squamous_Cell</m> @DISEASE_MESH:D002294 @@@cutaneous squamous cell carcinoma@@@.", "citations": {"NLM": "Welponer T, Weber DD, Trattner L, Tockner B, Aminzadeh-Gohari S, Leb-Reichl V, Kaufmann A, Zauner R, Wimmer M, Wally V, Felder TK, Strunk D, Koller U, Bauer JW, Kofler B, Guttmann-Gruber C, Hofbauer JP. Metformin shows anti-neoplastic properties by inhibition of oxidative phosphorylation and glycolysis in epidermolysis bullosa-associated aggressive cutaneous squamous cell carcinoma. J Eur Acad Dermatol Venereol. 2023 Sep 5;():. PMID: 37669776", "BibTeX": "@article{37669776, title={Metformin shows anti-neoplastic properties by inhibition of oxidative phosphorylation and glycolysis in epidermolysis bullosa-associated aggressive cutaneous squamous cell carcinoma.}, author={Welponer T and Weber DD and Trattner L and Tockner B and Aminzadeh-Gohari S and Leb-Reichl V and Kaufmann A and Zauner R and Wimmer M and Wally V and Felder TK and Strunk D and Koller U and Bauer JW and Kofler B and Guttmann-Gruber C and Hofbauer JP}, journal={J Eur Acad Dermatol Venereol}}"}}]}